 |
|
|
|
 |
|
|
| Article 1 to 8 out of 8 concerning Jerini AG
|
-
Jerini sells onself to british Shire
(07/07/2008)
Jerini AG for an equity purchase price of EUR 328 million
Shire Limited, the global specialty biopharmaceutical company, announced that Maia Elfte Vermögensverwaltungs-GmbH, to be renamed "Shire Deutschland Investments GmbH", a German indirect subsidiary of Shire Limited, will launch a voluntary public ...
-
Jerini Ophthalmic Treats First Patient in Phase I Trial for Age-related Macular Degeneration
(10/10/2007)
Jerini AG announced that its wholly-owned subsidiary, Jerini Ophthalmic, Inc., has treated the first patient in its Phase I clinical trial evaluating JSM 6427 for the treatment of age-related macular degeneration (AMD). JSM 6427 is a small molecule ...
-
Jerini expands collaboration with Baxter to develop non-intraveneous hemophilia therapy
(02/07/2007)
Jerini AG announced the expansion of their current research collaboration with Baxter AG for the development of a non-intravenous therapy for the treatment of hemophilia. The companies have initiated two additional programs aimed at novel targets, ...
-
Jerini Announces Positive Results from Two Phase III Trials of Icatibant for the Treatment of Hereditary Angioedema
(09/25/2006)
Jerini AG announced the results of its two pivotal Phase III trials (FAST-1 and FAST-2) for the subcutaneous treatment of hereditary angioedema (HAE). In the FAST-2 study, the primary endpoint was reached, showing a significant reduction in the time ...
-
Jerini AG presents clinical development update for Icatibant in the treatment of hereditary angioedema
(03/07/2006)
Jerini AG announced that clinical trial progress from its ongoing Phase III clinical trial for hereditary angioedema (HAE) was presented by Dr. Alvin Davis, Harvard Medical School, at the American Academy of Allergy Asthma and Immunology Conference ...
-
JERINI INITIATES PIVOTAL REGISTRATION STUDY FOR ICATIBANT IN HEREDITARY ANGIOEDEMA
(09/08/2004)
Jerini announced today the start of its US and Canadian pivotal registration study with Icatibant for the treatment of hereditary angioedema (HAE). An Investigational New Drug Application (IND) and Clinical Trials Application (CTA) have been filed ...
-
PamGene and JPT Join Forces
(06/24/2004)
Partnership pioneers a new approach to kinase research
Den Bosch/The Netherlands, Berlin/Germany: PamGene International BV and Jerini Peptide Technologies (JPT), a Division of Jerini AG, have established a collaboration to provide a new technology for kinase studies. PamGene's ability to generate ...
-
Jerini AG reaches milestones in two research alliances with Baxter Healthcare
(11/07/2003)
Jerini AG announces that the company has successfully passed first milestones in two research alliances entered into with Baxter in 2001 and 2002. Jerini has optimized peptide lead molecules identified against two undisclosed targets applying its ...
Additional information
Jerini AG
Berlin, Germany
Company
|
|
|
|
|
|
Top
